Intravenous magnesium sulfate for prevention of vancomycin plus piperacillin-tazobactam induced acute kidney injury in critically ill patients: An open-label, placebo-controlled, randomized clinical trial.
Hossein KhaliliHamid RahmaniMostafa MohammadiMohamadreza SalehiZahra MostafaviPublished in: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences (2021)
Administration of magnesium sulfate with the target serum levels around 3 mg/dL reduced the incidence of AKI in critically ill patients who were receiving VPT as empric therapy.
Keyphrases
- double blind
- placebo controlled
- acute kidney injury
- high glucose
- diabetic rats
- risk factors
- methicillin resistant staphylococcus aureus
- high dose
- clinical trial
- gram negative
- squamous cell carcinoma
- randomized controlled trial
- oxidative stress
- phase ii
- low dose
- phase ii study
- staphylococcus aureus
- multidrug resistant